Compare IDEXX Laboratories, Inc. (IDXX) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs PAGSEG Inc — how do they compare? IDEXX Laboratories, Inc. trades at $556.84 (market cap $44.48B), while PAGSEG Inc trades at $9.31 (market cap $2.60B). The key difference: IDEXX Laboratories, Inc. is far larger — about 17.1× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.19% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PAGS | |
|---|---|---|
Market Cap | $44.48B | $2.60B |
Sector | Health | Technology |
52-Week High | $766.68 | $12.00 |
52-Week Low | $520.87 | $7.75 |
Enterprise Value | $45.38B | $10.23B |
Dividend Yield | — | 11.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
PAGS trades at $9.29, up 2.77% today, with bearish technical signals but strong fundamentals including a P/E of 6.4 and net income margin of 10.4%. Recent earnings showed a Q1 2026 miss at $0.39 EPS versus $0.40 expected, while Q4 2025 beat expectations. The company maintains robust cash flow from operations of $7.56B in 2025 and declared a $0.26 dividend for H1 2026, payable June 1, 2026.
The stock presents a value opportunity with low valuation multiples and solid profitability, though technical weakness and mixed earnings create near-term uncertainty. Risks include Brazilian macroeconomic sensitivity and competitive pressures, but analyst consensus is strongly bullish with 62.5% buy ratings, suggesting upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
